The content on this site is intended for healthcare professionals only
Prof Engert talks at a press conference at the 17th Congress of the European Haematology Association in Amsterdam.
He presented data from the GHSG HD15 trial on reduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma.
Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumour control and overall survival compared to previously used regimens.
In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.
They thus conducted a prospectively randomised clinical trial comparing the standard of care (8 x BEACOPPescalated) with two reduced-intensity chemotherapy variants.
Filming supported by Amgen
Understanding AL amyloidosis: Treatment and diagnosis
New classification for identifying HR myeloma based on cytogenetic abnormalities
Multiple Myeloma: evolving paradigm - Panel Discussion
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
Multiple myeloma in a resource constrained setting
The evolving paradigm in management of Multiple Myeloma
The evolving paradigm in management of Multiple Myeloma
Multiple myeloma (A cancer arising from plasma cells)
Multiple myeloma (A cancer arising from plasma cells)
